Objective To study the value of radiofrequency ablation combined with targeted therapy in the treatment of patients with peripheral non-small cell lung cancer at stage Ⅲ and Ⅳ under ultrasound and CT.Meth-ods 80 patients with peripheral non-small cell lung cancer at stage ⅢandⅣwere randomly divided into the obser-vation group and the control group.All of them were treated with paclitaxel,cisplatin and gefitinib,while the obser-vation group was additionally treated with percutaneous radio frequency ablation.The concentration of tumor markers in serum and clinical efficacy of near future and long-term and adverse reaction were observed and compared between the two groups.Results After the treatment,the concentration of EGFR,SCC,CEA and CA1 25 were lower in the observation group than in the control group (P<0.05 ).Conclusion The treatment of radiofrequency ablation com-bined with targeted therapy can improve the clinical efficiency in the treatment of patients with peripheral non-small cell lung cancer at stage Ⅲ and Ⅳ,with high safety and minor trauma.%目的：研究超声与CT引导下射频消融联合靶向治疗对周围型中晚期（Ⅲ与Ⅳ期）非小细胞肺癌患者的治疗价值。方法选取80例周围型中晚期非小细胞肺癌患者随机分为对照组与观察组，每组均为40例。两组患者均给予吉非替尼联合顺铂与紫杉醇靶向治疗，观察组在靶向治疗的基础上行在超声与CT引导下经皮射频消融术，观察两组治疗后的近期及远期临床疗效、不良反应与治疗前后外周血清肿瘤标记物的浓度。结果治疗后观察组临床疗效均优于对照组（P＜0.05），治疗后两组外周血清表皮生长因子受体（EGFR）、鳞状细胞癌相关抗原（SCC）、癌胚抗原（CEA）、糖类抗原（CA125）浓度均明显低于治疗前（P＜0.05），治疗后观察组外周血清EGFR、SCC、CEA、CA125浓度均明显低于对照组（P＜0.05），观察组术后出现咳嗽、胸痛、发热、咯血、气胸，两组靶向治疗后均出现恶心、恶心伴呕吐、骨髓抑制，无统计学差异（P＞0.05）。结论超声与CT引导下射频消融术联合靶向治疗对转移灶较少的周围型中晚期非小细胞肺癌能很好的提高临床疗效，是一种安全可靠且创伤较小的治疗方法，有很好的临床应用前景。
展开▼
